ty-2699a

TY-2699a is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinase 7 (CDK7), developed by TYK Medicines. It selectively targets and inhibits CDK7, a key regulator of cell cycle progression and transcription. By inhibiting CDK7 activity, TY-2699a disrupts cell cycle control and transcriptional processes in cancer cells, leading to cell cycle arrest (notably at the G2/M phase) and apoptosis. This mechanism offers potential antineoplastic effects across various solid tumors—including breast (notably triple-negative breast cancer), ovarian, small cell lung cancer—and other locally advanced or metastatic malignancies. Preclinical studies have demonstrated promising pharmacokinetics and safety profiles for this agent. As of early 2025, it is in Phase 1 clinical trials in China for multiple solid tumor indications[1][2][3][4][5][8].